
DEFINITIONS

In this prospectus, unless the context otherwise requires, the following terms shall have the following meanings. Certain technical terms are explained in the section headed “Glossary of Technical Terms” in this prospectus.

“Adimab”	Adimab, LLC, a company registered in Delaware, the United States, located at 7 Lucent Drive, Lebanon, NH 03766
“affiliate”	with respect to any specified person, any other person, directly or indirectly, controlling or controlled by or under direct or indirect common control with such specified person
“Ally Bridge”	Ally Bridge LB – Sunshine Limited (formerly known as “ABLB-Beauty Limited”), a business company incorporated under the laws of the British Virgin Islands on September 7, 2015 and one of our Pre-IPO Investors
“Application Form(s)”	WHITE Application Form(s), YELLOW Application Form(s) and GREEN Application Form(s) or, as the context so requires, any of them, which is used in relation to the Hong Kong Public Offering
“Articles” or “Articles of Association”	the thirteenth amended and restated articles of association of the Company adopted on October 15, 2018 with effect from Listing, as amended from time to time, a summary of which is set out in the section headed “Appendix III – Summary of the Constitution of the Company and Cayman Companies Law”
“Asia Ventures”	Asia Ventures II L.P., a limited partnership established under the laws of Bermuda and one of our Pre-IPO Investors
“associate(s)”	has the meaning ascribed to it under the Listing Rules
“Beacon Bioventures” or “F-Prime Capital”	F-Prime Capital Partners Healthcare Fund II LP (formerly “Beacon Bioventures Fund II Limited Partnership”), a limited partnership established under the laws of Delaware, U.S. and one of our Pre-IPO Investors

DEFINITIONS

“Beijing Jun Lian”	Beijing Jun Lian Yi Kang Equity Investment Partnership (Limited Partnership) (北京君聯益康股權投資合夥企業 (有限合夥)), a limited partnership established under the laws of the PRC on November 23, 2015 and one of our Pre-IPO Investors
“Board”	the board of Directors of the Company
“business day”	any day (other than a Saturday, Sunday or public holiday in Hong Kong) on which banks in Hong Kong are generally open for normal banking business
“Capital Group Private Markets”	Seacliff (Cayman) Ltd. and Dwyer (Cayman) Ltd.
“Category 1”	the category 1 under the registration category for therapeutic biological products as provided in Annex 3 to the Administrative Measures for Drug Registration (《藥品註冊管理辦法》), which refer to biological products that have not been marketed anywhere in the world
“Category 2”	the category 2 under the registration category for therapeutic biological products as provided in Annex 3 to the Administrative Measures for Drug Registration (《藥品註冊管理辦法》), which refer to monoclonal antibody
“Cayman Companies Law”	the Companies Law, Cap. 22 (Law 3 of 1961) of the Cayman Islands, as amended or supplemented from time to time
“Cayman Registrar”	the Registrar of Companies of the Cayman Islands
“CBC”	CBC SPVIII Limited, a company incorporated under the laws of Hong Kong on October 23, 2014 and one of our Pre-IPO Investors
“CCASS”	the Central Clearing and Settlement System established and operated by HKSCC
“CCASS Clearing Participant”	a person admitted to participate in CCASS as a direct clearing participant or a general clearing participant
“CCASS Custodian Participant”	a person admitted to participate in CCASS as a custodian participant

DEFINITIONS

“CCASS Investor Participant”	a person admitted to participate in CCASS as an investor participant who may be an individual or joint individuals or a corporation
“CCASS Participant”	a CCASS Clearing Participant, a CCASS Custodian Participant or a CCASS Investor Participant
“Cheng Yu Investments”	Cheng Yu Investments Limited, a business company incorporated under the laws of the British Virgin Islands and one of our Pre-IPO Investors
“China” or “PRC”	the People’s Republic of China and for the purposes of this prospectus only, except where the context requires otherwise, excludes Hong Kong, Macau and Taiwan
“China Life”	China Life Chengda (Shanghai) Healthcare Industry Equity Investment Center (Limited Partnership) (國壽成達(上海)健康產業股權投資中心(有限合夥)), a limited partnership established under the laws of the PRC on November 11, 2016 and one of our Pre-IPO Investors
“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Companies (Winding Up and Miscellaneous Provisions) Ordinance”	the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Company”, “our Company”, or “the Company”	Innovent Biologics, Inc. (信達生物製藥), an exempted company with limited liability incorporated under the laws of the Cayman Islands on April 28, 2011
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“connected transaction(s)”	has the meaning ascribed to it under the Listing Rules
“Cormorant Global Healthcare”	Cormorant Global Healthcare Master Fund, LP, an exempted limited partnership registered under the laws of Cayman Islands on April 2, 2013 and one of our Pre-IPO Investors

DEFINITIONS

“Cormorant Private Healthcare”	Cormorant Private Healthcare Fund I, LP, a limited partnership incorporated under the laws of Delaware, US on October 14, 2015 and one of our Pre-IPO Investors
“Cowin China”	Cowin China Growth Fund I, L.P., an exempted limited partnership registered under the laws of the Cayman Islands on November 23, 2012 and one of our Pre-IPO Investors
“CRF Investment”	CRF Investment Holdings Company Limited, an exempted limited liability company incorporated under the laws of the Cayman Islands on November 14, 2017 and one of our Pre-IPO Investors
“CRMA”	CRMA SPV, L.P., an exempted limited partnership registered under the laws of the Cayman Islands on October 6, 2015 and one of our Pre-IPO Investors
“CRO”	Contract research organization
“CSRC”	China Securities Regulatory Commission
“CSVC”	China-Singapore Suzhou Industrial Park Ventures Co., Ltd. (中新蘇州工業園區創業投資有限公司), a company incorporated under the laws of the PRC on November 28, 2001 and one of our Pre-IPO Investors
“Director(s)”	the director(s) of the Company
“EGFR”	epidermal growth factor receptor
“Eli Lilly”	Eli Lilly and Company, a U.S.A. company, organized and existing under the laws of the State of Indiana on January 17, 1901, having a place of business at Lilly Corporate Center, Indianapolis, Indiana 46285
“EMA”	European Medicines Agency
“Equity Plans”	the Pre-IPO Share Incentive Plan, the Post-IPO ESOP and the RS Plan
“Existing Articles”	the twelfth amended and restated memorandum and articles of association of the Company adopted by special resolution of the shareholders effective on June 1, 2018

DEFINITIONS

“Foreign Investment Law”	the Draft Foreign Investment Law (中華人民共和國外國投資法) published by the MOFCOM in January 2015
“Frost & Sullivan”	Frost & Sullivan (Beijing) Inc., Shanghai Branch Co., an independent market research and consulting company that provides market survey and consulting services
“Frost & Sullivan Report”	an industry report prepared by Frost & Sullivan on the worldwide biologics market, which was commissioned by us
“Future Industry”	Future Industry Investment Fund LP (先進製造產業投資基金(有限合夥)), a limited partnership established under the laws of the PRC on May 11, 2015 and one of our Pre-IPO Investors
“Global Offering”	the Hong Kong Public Offering and the International Offering
“ GREEN Application Form(s)”	the application form(s) to be completed by the White Form eIPO Service Provider, Computershare Hong Kong Investor Services Limited
“Group”, “our Group”, “the Group”, “we”, “us”, or “our”	the Company and its subsidiaries from time to time
“Highsino”	Highsino Group Limited, a business company incorporated under the laws of the British Virgin Islands and one of our Pre-IPO Investors
“Hillhouse INOV”	Hillhouse INOV Holdings Limited, a business company incorporated under the laws of the British Virgin Islands and one of our Pre-IPO Investors
“HKSCC”	Hong Kong Securities Clearing Company Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited
“HKSCC Nominee”	HKSCC Nominees Limited, a wholly-owned subsidiary of HKSCC
“Hong Kong” or “HK”	the Hong Kong Special Administrative Region of the PRC

DEFINITIONS

“Hong Kong dollars” or “HK dollars” or “HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong Offer Shares”	the 23,635,000 Shares initially being offered for subscription in the Hong Kong Public Offering (subject to reallocation as described in the section headed “Structure of the Global Offering” in this prospectus)
“Hong Kong Public Offering”	the offer of the Hong Kong Offer Shares for subscription by the public in Hong Kong at the Offer Price (plus brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the terms and subject to the conditions described in this prospectus and the Application Forms, as further described in the section headed “Structure of the Global Offering” in this prospectus
“Hong Kong Securities and Futures Ordinance” or “SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Hong Kong Share Registrar”	Computershare Hong Kong Investor Services Limited
“Hong Kong Underwriters”	the underwriters of the Hong Kong Public Offering as listed in the section headed “Underwriting – Hong Kong Underwriters”
“Hong Kong Underwriting Agreement”	the underwriting agreement dated October 16, 2018 relating to the Hong Kong Public Offering entered into among, inter alia, the Joint Global Coordinators, the Joint Sponsors, the Hong Kong Underwriters and the Company, as further described in the section headed “Underwriting”
“Hua Yuan”	Hua Yuan International Limited, a company incorporated under the laws of Hong Kong on September 26, 2006 and a wholly-owned subsidiary of CSVC
“IFRS”	International Financial Reporting Standards, as issued from time to time by the International Accounting Standards Board

DEFINITIONS

“Independent Third Party(ies)”	any entity or person who is not a connected person of the Company within the meaning ascribed thereto under the Listing Rules
“Innovent HK”	Innovent Biologics (HK) Limited, a company incorporated under the laws of Hong Kong on May 17, 2011 and one of the Company’s principal subsidiaries
“Innovent Suzhou”	Innovent Biologics (Suzhou) Co., Ltd. (信達生物製藥(蘇州)有限公司), a company established under the laws of the PRC on August 24, 2011 and one of the Company’s principal subsidiaries
“Innovent Technology”	Suzhou Innovent Biotechnology Co., Ltd. (蘇州信達生物科技有限公司), a company incorporated under the laws of the PRC on July 8, 2013
“International Offering”	the conditional placing of the International Offering Shares at the Offer Price outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and in the United States to QIBs only in reliance on Rule 144A or any other available exemption from the registration requirement under the U.S. Securities Act, in each case on and subject to the terms and conditions of the International Underwriting Agreement, as further described in the section headed “Structure of the Global Offering”
“International Offering Shares”	the 212,715,000 Shares being initially offered for subscription at the Offer Price under the International Offering together, where relevant, with any additional Shares that may be issued pursuant to any exercise of the Over-allotment Option, subject to reallocation as described under the section headed “Structure of the Global Offering”
“International Underwriters”	the underwriters of the International Offering
“International Underwriting Agreement”	the international underwriting agreement relating to the International Offering and expected to be entered into by, among others, the Company, the Joint Global Coordinators and the International Underwriters on or about the Price Determination Date, as further described in the section headed “Underwriting”

DEFINITIONS

“Investors’ Rights Agreement”	the eighth amended and restated investors’ rights agreements entered into on June 1, 2018 by and among the Company, F-Prime Capital, Asia Ventures, Suzhou Industrial Park, Lilly Asia, Hua Yuan, Suzhou Frontline, Life Sciences, LC Fund, LC Parallel Fund, Cheng Yu Investments, TLS Beta, LAV Opus Limited, LAV Orion Limited, LAV Agility Limited, Hillhouse INOV, Cowin China, CBC, Future Industry Investment (BVI) Co., Limited, Pingan Inno Limited, Easy Swift Limited, Shanghai Sa Wang, LC Healthcare, Highsino, Shanghai Pengfang Health Consultation Co., Ltd., Shanghai Chiyi, Xiangan Inno Limited, China Life, Seacliff (Cayman) Ltd., Dwyer (Cayman) Ltd., Taikang AMC HK, Cormorant Private Healthcare, Cormorant Global Healthcare, CMRA, Rock Springs, CRF Investment and Ally Bridge
“JCO”	Journal of Clinical Oncology
“Jiaxing Xiang’an”	Jiaxing Xiang’an Equity Investment Fund Partnership (Limited Partnership) (嘉興祥安股權投資基金合夥企業(有限合夥)), a limited partnership established under the laws of the PRC on July 19, 2016 and one of our Pre-IPO Investors
“Joint Bookrunners”	Morgan Stanley Asia Limited (in relation to the Hong Kong Public Offering) and Morgan Stanley & Co. International plc (in relation to the International Offering), Goldman Sachs (Asia) L.L.C., J.P. Morgan Securities (Asia Pacific) Limited (in relation to the Hong Kong Public Offering), J.P. Morgan Securities plc (in relation to the International Offering), China Merchants Securities (HK) Co., Limited, Huatai Financial Holdings (Hong Kong) Limited and The Hongkong and Shanghai Banking Corporation Limited
“Joint Global Coordinators”	Morgan Stanley Asia Limited, Goldman Sachs (Asia) L.L.C., J.P. Morgan Securities (Asia Pacific) Limited, China Merchants Securities (HK) Co., Limited and Huatai Financial Holdings (Hong Kong) Limited

DEFINITIONS

“Joint Lead Managers”	Morgan Stanley Asia Limited (in relation to the Hong Kong Public Offering) and Morgan Stanley & Co. International plc (in relation to the International Offering), Goldman Sachs (Asia) L.L.C., J.P. Morgan Securities plc (in relation to International Offering), J.P. Morgan Securities (Asia Pacific) Limited (in relation to Hong Kong Public Offering), China Merchants Securities (HK) Co., Limited, Huatai Financial Holdings (Hong Kong) Limited and The Hongkong and Shanghai Banking Corporation Limited
“Joint Sponsors”	Morgan Stanley Asia Limited, Goldman Sachs (Asia) L.L.C., J.P. Morgan Securities (Far East) Limited and China Merchants Securities (HK) Co., Limited
“Latest Practicable Date”	October 9, 2018, being the latest practicable date for ascertaining certain information in this prospectus before its publication
“LAV Agility”	LAV Agility Limited, a business limited liability company incorporated under the laws of the British Virgin Islands and one of our Pre-IPO Investors
“LAV Opus”	LAV Opus Limited, a business limited liability company incorporated under the laws of the British Virgin Islands and one of our Pre-IPO Investors
“LAV Orion”	LAV Orion Limited, a business limited liability company incorporated under the laws of the British Virgin Islands and one of our Pre-IPO Investors
“LC Fund”	LC Fund VI, L.P., an exempted limited partnership incorporated under the laws of the Cayman Islands and one of our Pre-IPO Investors
“LC Healthcare”	LC Healthcare Fund I, L.P., an exempted limited partnership incorporated under the laws of the Cayman Islands and one of our Pre-IPO Investors
“LC Parallel Fund”	LC Parallel Fund VI, L.P., an exempted limited partnership incorporated under the laws of the Cayman Islands and one of our Pre-IPO Investors

DEFINITIONS

“Life Sciences”	China Life Sciences Access Fund, L.P., an exempted limited partnership incorporated under the laws of the Cayman Islands and one of our Pre-IPO Investors
“Lilly Asia”	Lilly Asia Ventures Fund II, L.P., an exempted limited partnership incorporated under the laws of the Cayman Islands and one of our Pre-IPO Investors
“Listing”	the listing of the Shares on the Main Board
“Listing Committee”	the Listing Committee of the Stock Exchange
“Listing Date”	the date, expected to be on October 31, 2018, on which the Shares are listed and on which dealings in the Shares are first permitted to take place on the Stock Exchange
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
“Main Board”	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operates in parallel with the Growth Enterprise Market of the Stock Exchange
“Memorandum” or “Memorandum of Association”	the thirteenth amended and restated memorandum of association of the Company adopted with effect from Listing, as amended from time to time, a summary of which is set out in the section headed “Appendix III – Summary of the Constitution of the Company and Cayman Companies Law”
“MOFCOM”	the Ministry of Commerce of the PRC (中華人民共和國商務部)
“NMPA”	China National Medical Products Administration (國家藥品監督管理局), successor to the China Food and Drug Administration (國家食品藥品監督管理總局)

DEFINITIONS

“Offer Price”	the final price per Offer Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) of not more than HK\$14.00 and expected to be not less than HK\$12.50, at which Hong Kong Offer Shares are to be subscribed for pursuant to the Hong Kong Public Offering and International Offering Shares are to be offered pursuant to the International Offering, to be determined as described in the section headed “Structure of the Global Offering – Pricing and Allocation” in this prospectus
“Offer Share(s)”	the Hong Kong Offer Shares and the International Offering Shares together, where relevant, with any additional Shares to be issued by the Company pursuant to the exercise of the Over-allotment Option
“Over-allotment Option”	the option to be granted by the Company to the Joint Global Coordinators under the International Underwriting Agreement pursuant to which the Company may be required by the Joint Global Coordinators to issue up to 35,452,000 additional Offer Shares, representing not more than 15% of the Offer Shares initially available under the Global Offering, at the Offer Price to cover overallocations in the International Offering, details of which are described in the section headed “Structure of the Global Offering” in this prospectus
“PCT”	the Patent Cooperation Treaty
“Post-IPO ESOP”	the post-IPO share option scheme adopted by the Company on June 12, 2018, the principal terms of which are set out in the section headed “Statutory and General Information – Equity Plans – Post-IPO ESOP” in Appendix IV
“PRC Legal Adviser”	Han Kun Law Offices
“Pre-IPO Investment(s)”	the pre-IPO investment(s) in the Company undertaken by the Pre-IPO Investors, details of which are set out in the section headed “History, Development and Corporate Structure”

DEFINITIONS

“Pre-IPO Investor(s)”	F-Prime Capital, Asia Ventures, Suzhou Industrial Park, Lilly Asia, CSVC, Hua Yuan (wholly-owned by CSVC), Suzhou Frontline, Life Sciences, LC Fund, LC Parallel Fund, Cheng Yu Investments, TLS Beta, LAV Opus, LAV Orion, LAV Agility, Hillhouse INOV, Cowin China, CBC, Future Industry, Future Industry Investment (BVI) Co., Limited (wholly-owned by Future Industry), Shenzhen Ping’an, Pingan Inno Limited (wholly-owned by Shenzhen Ping’an), Beijing Jun Lian, Easy Swift Limited (wholly-owned by Beijing Junlian), Shanghai Sa Wang, LC Healthcare, Highsino, Taikang, Shanghai Pengfang Health Consultation Co., Ltd. (wholly-owned by Taikang), Shanghai Chiyi, Jiaxing Xiang’an, Xiangan Inno Limited (wholly-owned by Jiaxing Xiang’an), China Life, Seacliff (Cayman) Ltd., Dwyer (Cayman) Ltd., Taikang AMC HK, Cormorant Private Healthcare, Cormorant Global Healthcare, CRMA, Rock Springs, CRF Investment and Ally Bridge
“Pre-IPO Share Incentive Plan”	the pre-IPO share incentive plan adopted by the Company on May 10, 2012 as amended from time to time, the principal terms of which are set out in the section headed “Statutory and General Information – Equity Plans – Pre-IPO Share Incentive Plan” in Appendix IV
“Price Determination Date”	the date, expected to be on or about Tuesday, October 23, 2018 (Hong Kong time) and in any event no later than Tuesday, October 30, 2018, on which the Offer Price is to be fixed by an agreement between the Company and the Joint Global Coordinators (on behalf of the Underwriters)
“Principal Share Registrar”	Maples Fund Services (Cayman) Limited
“prospectus”	this prospectus being issued in connection with the Hong Kong Public Offering
“QIB”	a qualified institutional buyer within the meaning of Rule 144A
“Regulation S”	Regulation S under the U.S. Securities Act

DEFINITIONS

“Right of First Refusal and Co-Sale Agreement”	the ninth amended and restated right of first refusal and co-sale agreement entered into on June 1, 2018 by and among the Company, LC Fund, LC Parallel Fund, Cheng Yu Investments, LC Healthcare, Highsino, TLS Beta, Hillhouse INOV, Cowin China, F-Prime Capital, Asia Ventures, Lilly Asia, LAV Opus Limited, LAV Agility Limited, Life Sciences, Suzhou Industrial Park, Suzhou Frontline, Hua Yuan, Future Industry, Pingan Inno Limited, Easy Swift Limited, CBC, Shanghai Sa Wang, China Life, Shanghai Pengfang, Shanghai Chiyi, Xiangan Inno Limited, Seacliff (Cayman) Ltd., Dwyer (Cayman) Ltd., Scott Matthew Wheelwright, Zheng Jia, De-Chao Michael Yu, Charles Leland Cooney, Taikang AMC HK, Cormorant Private Healthcare, Cormorant Global Healthcare, CMRA, Rock Springs, CRF Investment and Ally Bridge
“RMB” or “Renminbi”	Renminbi, the lawful currency of China
“Rock Springs”	Rock Springs Capital Master Fund LP, an exempted limited partnership registered under the Exempted Limited Partnership Law (as amended) of the Cayman Islands on July 25, 2013 and one of our Pre-IPO Investors
“RS Plan”	the restricted share plan adopted by the Company on October 15, 2018, the principal terms of which are set out in the section headed “Statutory and General Information – Equity Plans – RS Plan” in Appendix IV
“Rule 144A”	Rule 144A under the U.S. Securities Act
“SAFE”	the State Administration of Foreign Exchange of the PRC
“SEC”	the Securities and Exchange Commission of the United States
“Series A Preferred Shareholders”	the holder of the Series A Preferred Shares

DEFINITIONS

“Series A Preferred Shares”	the series A convertible redeemable preferred shares of the Company with a current par value of US\$0.00001 per share which are in issue and held by the Series A Preferred Shares Shareholders pursuant to the Round 2 Cayman Investment, details of which are described in the section headed “History, Development and Corporate Structure”
“Series B Preferred Shareholders”	the holder of the Series B Preferred Shares
“Series B Preferred Shares”	the series B convertible redeemable preferred shares of the Company with a current par value of US\$0.00001 per share which are in issue and held by the Series B Preferred Shares Shareholders pursuant to the Round 4 Cayman Investment, Round 5 Cayman Investment and Round 7 Cayman Investment, details of which are described in the section headed “History, Development and Corporate Structure”
“Series C Preferred Shareholders”	the holder of the Series C Preferred Shares
“Series C Preferred Shares”	the series C convertible redeemable preferred shares of the Company with a current par value of US\$0.00001 per share which are in issue and held by the Series C Preferred Shares Shareholders pursuant to the Round 6 Cayman Investment and Round 8 Cayman Investment, details of which are described in the section headed “History, Development and Corporate Structure”
“Series D Preferred Shareholders”	the holder of the Series D Preferred Shares
“Series D Preferred Shares”	the series D convertible redeemable preferred shares of the Company with a current par value of US\$0.00001 per share which are in issue and held by the Series D Preferred Shares Shareholders pursuant to the Round 9 Cayman Investment, details of which are described in the section headed “History, Development and Corporate Structure”
“Series E Preferred Shareholders”	the holder of the Series E Preferred Shares

DEFINITIONS

“Series E Preferred Shares”	the series E convertible redeemable preferred shares of the Company with a current par value of US\$0.00001 per share which are in issue and held by the Series E Preferred Shares Shareholders pursuant to the Round 10 Cayman Investment and Round 11 Cayman Investment, details of which are described in the section headed “History, Development and Corporate Structure”
“SFC”	the Securities and Futures Commission of Hong Kong
“Shanghai Chiyi”	Shanghai Chiyi Investment Management Centre (Limited Partnership) (上海赤易投資管理中心(有限合夥)), a limited partnership established under the laws of the PRC on December 3, 2015 and one of our Pre-IPO Investors
“Shanghai Sa Wang”	Shanghai Sa Wang Investment Center (Limited Partnership) (上海薩旺投資中心(有限合夥)), a limited liability incorporated under the laws of the PRC on March 14, 2016 and one of our Pre-IPO Investors
“Shareholder(s)”	holder(s) of the Share(s)
“Share(s)”	ordinary share(s) in the share capital of the Company
“Shenzhen Ping’an”	Shenzhen Ping’an Healthcare & Technology Equity Investment Partnership (Limited Partnership) (深圳市平安健康科技股權投資合夥企業(有限合夥)), a limited partnership established under the laws of the PRC on October 9, 2015 and one of our Pre-IPO Investors
“Stabilization Manager”	Morgan Stanley Asia Limited
“Stock Borrowing Agreement”	the stock borrowing agreement expected to be entered into on or about the Price Determination Date between the Stabilization Manager and Dr. De-Chao Michael Yu, pursuant to which Dr. De-Chao Michael Yu will agree to lend up to 35,452,000 Shares to the Stabilization Manager on terms set forth therein
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary(ies)”	has the meaning ascribed to it in section 15 of the Companies Ordinance

DEFINITIONS

“substantial shareholder”	has the meaning ascribed to it in the Listing Rules
“Suzhou Frontline”	Suzhou Frontline Bioventures Venture Capital Investment Partnership (LP) (蘇州通和創業投資合夥企業(有限合夥)), a limited partnership established under the laws of the PRC on September 12, 2012 and one of our Pre-IPO Investors
“Suzhou Industrial Park”	Suzhou Industrial Park Biotech Development Co., Ltd, (蘇州工業園區生物產業發展有限公司), a company incorporated under the laws of the PRC on October 17, 2005 and one of our Pre-IPO Investors
“Taikang”	Taikang Life Insurance Co., Ltd. (泰康人壽保險有限責任公司), a company incorporated under the laws of the PRC on November 28, 2016 and one of our Pre-IPO Investors
“Taikang AMC HK”	Taikang Asset Management (Hong Kong) Company Limited, a company incorporated under the laws of Hong Kong on November 9, 2007 and one of our Pre-IPO Investors
“Takeovers Code”	The Code on Takeovers and Mergers issued by the SFC, as amended, supplemented or otherwise modified from time to time
“TLS Beta”	TLS BETA PTE. LTD., a company incorporated under the laws of Singapore on January 7, 2005 and one of our Pre-IPO Investors
“Track Record Period”	the two financial years ended December 31, 2016 and 2017 and the six months ended June 30, 2018
“Underwriters”	the Hong Kong Underwriters and the International Underwriters
“Underwriting Agreements”	the Hong Kong Underwriting Agreement and the International Underwriting Agreement
“United States”, “U.S.” or “US”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“US dollars”, “U.S. dollars” or “US\$”	United States dollars, the lawful currency of the United States

DEFINITIONS

“US FDA” or “FDA”	the U.S. Food & Drug Administration of the U.S. Department of Health and Human Services
“U.S. Securities Act”	United States Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder
“ WHITE Application Form(s)”	the form of application for the Hong Kong Offer Shares for use by the public who require such Hong Kong Offer Shares to be issued in the applicants’ own name
“ White Form eIPO ”	the application for Hong Kong Offer Shares to be issued in the applicant’s own name, submitted online through the designated website of White Form eIPO Service Provider, www.eipo.com.hk
“ White Form eIPO Service Provider”	Computershare Hong Kong Investor Services Limited
“ YELLOW Application Form(s)”	the form of application for the Hong Kong Offer Shares for use by the public who require such Hong Kong Offer Shares to be deposited directly into CCASS
“%”	per cent

Unless otherwise expressly stated or the context otherwise requires, all data in this prospectus is as of the date of this prospectus.

The English names of the PRC entities, PRC laws or regulations, and the PRC governmental authorities referred to in this prospectus are translations from their Chinese names and are for identification purposes. If there is any inconsistency, the Chinese names shall prevail.

Certain amounts and percentage figures included in this prospectus have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables may not be an arithmetic aggregation of the figures preceding them.